Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-17

Study Completion Date

2019-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the safety and find the tolerated ultrasound dose of transient opening of the blood-brain barrier (BBB) by using the NaviFUS System in recurrent GBM patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients

NCT04988750

Recurrent Glioblastoma

UNKNOWN NA

The Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier

NCT04063514

Low Grade Glioma of Brain

ENROLLING_BY_INVITATION NA

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

NCT05281731

Glioblastoma Glioblastoma Multiforme

RECRUITING NA

Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption

NCT05733312

Brain Tumor

RECRUITING NA

Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

NCT00870129

Brain Cancer Glioma

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a feasibility, open-label, single-arm, and dose escalation study. Eligible patients will be enrolled through the process of informed consent. Patients will be assigned into different dose groups generated from the NaviFUS System to transiently open the BBB in patients with recurrent GBM who will undergo surgery within 2 weeks. The focused ultrasound (FUS) dose is selected based on the results of pre-clinical Good Laboratory Practice (GLP) safety studies as well as other non-GLP primate studies. This study will evaluate the safety and the tolerated ultrasound dose of temporary disruption of the BBB in patients with recurrent GBM. To find the tolerated ultrasound dose, the data and safety monitoring board (DSMB) will review the study data and provide the recommendations regarding continuation, termination, or other modifications of the study based on evaluation of observed adverse effects of the intervention. The extent and magnitude of BBB opening will be evaluated using of dynamic contrast-enhanced MRI (DCE-MRI).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Multiforme Brain Tumor Glioblastoma Glioma Neoplasms Neoplasms, Nerve Tissue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NaviFUS System

NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB

Group Type EXPERIMENTAL

NaviFUS System

Intervention Type DEVICE

BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NaviFUS System

BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with recurrent GBM and will undergo surgery
* Able to give written informed consent for the participation in the trial
* Adult male/female patients \> 20 years of age
* Patients if already on radiotherapy, a gap of 7 days shall be maintained between the last day of radiotherapy and the day of screening
* Patients if already on the steroids treatment, then should be on a stable dose of steroids for at least 7 days prior to screening
* Body mass index (BMI) ≥17 kg / m2
* Patients with life expectancy ≥ 3 months
* Able to comply with study requirements in the opinion of the investigator
* Adequate hepatic, renal, coagulation, and hematopoietic function

* Hemoglobin ≥ 10 g/dL
* Platelets ≥ 100,000/mm3
* Neutrophils ≥ 1,500/mm3
* Normal creatinine clearance ≥ 50mL/min
* Alanine transaminase (ALT) \< 3 x upper limit of normal (ULN)
* Aspartate transaminase (AST) \< 3 x ULN
* Prothrombin time ≤ 1.2 x ULN
* International Normalized Ratio (INR) \< 1.5
* Bilirubin \< 2 x ULN
* Patients with the ROI for FUS exposure are located close to the cortex with at least 20 mm distance beneath the skull bone and the ROI is not in the deep center brain with crucial brain functions, such as in the region of brain stem, or motor or speech regions
* The Karnofsky performance status (KPS) in the patient must be \> 60

Exclusion Criteria

* Patients at screening visit have arteriovenous malformation (AVM) or cerebral aneurysm
* Use of any recreational drugs or history of drug addiction
* Pregnant or breast-feeding women
* The receipt of an investigational drug, or participation in a drug research study within a period of one month prior to the first FUS exposure
* Known sensitivity/allergy to MRI contrast agents, CT contrast agents, SonoVue®, or any of its components
* Any other condition that, in the investigator's judgment, might increase the risk to the patients or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study
* Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints
* Patients who have hemorrhage or cyst within the ROI
* Severe hypertension at screening (diastolic blood pressure \> 100 mmHg on medication)
* Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week prior to study treatment or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month prior to study treatment

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No